Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?

Schoretsanitis, Georgios; Haen, Ekkehard; Hiemke, Christoph; Gründer, Gerhard; Stegmann, Benedikt; Schruers, Koen; Veselinovic, Tania; Lammertz, Sarah; Paulzen, Michael (2016). Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? International clinical psychopharmacology, 31(5), pp. 259-264. Wolters Kluwer Lippincott Williams & Wilkins 10.1097/YIC.0000000000000131

[img]
Preview
Text
Schoretsanitis et al Risperidone-induced extrapyramidal side effects_f.pdf - Published Version
Available under License Publisher holds Copyright.

Download (175kB) | Preview

Antipsychotic drugs can induce various undesirable adverse motor reactions, such as extrapyramidal side effects (EPS). A widely accepted pharmacodynamic mechanism underlying EPS includes an increase in striatal D2-receptor occupancy. However, less is known about the pharmacokinetic background of EPS. The aim of this study was to analyze in-vivo possible pharmacokinetic patterns underlying biperiden-treated EPS in risperidone (RIS)-medicated patients. A large therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-hydroxyrisperidone (9-OH-RIS) of 2293 adult inpatients and outpatients was analyzed. Two groups were compared: a group receiving RIS (n=772) and a group comedicated with biperiden (n=68). Plasma concentrations, dose-adjusted plasma concentrations (C/D) of RIS, 9-OH-RIS, and active moiety (AM) (RIS+9-OH-RIS) as well as ratios of concentrations for metabolite to parent drug (9-OH-RIS/RIS) were computed. We compared the plasma concentrations of the different compounds between the two groups considering the prescription of biperiden as an indirect report of EPS. The daily dosage of RIS did not differ between groups. No differences were detected in case of plasma concentrations and C/D of RIS and active metabolite between the groups. However, plasma concentrations of the AM were significantly higher in the comedicated group (P=0.032) and showed a trend in terms of the active metabolite 9-OH-RIS (P=0.053). Data indicate enhanced AM plasma concentrations of RIS in patients comedicated with biperiden as an EPS treatment. This might underscore an association between higher plasma concentrations of the AM and treatment-requiring EPS.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Translational Research Center

UniBE Contributor:

Schoretsanitis, Georgios

ISSN:

1473-5857

Publisher:

Wolters Kluwer Lippincott Williams & Wilkins

Language:

English

Submitter:

Georgios Schoretsanitis

Date Deposited:

15 Feb 2017 12:25

Last Modified:

15 Feb 2018 14:50

Publisher DOI:

10.1097/YIC.0000000000000131

PubMed ID:

27167902

BORIS DOI:

10.7892/boris.91632

URI:

https://boris.unibe.ch/id/eprint/91632

Actions (login required)

Edit item Edit item
Provide Feedback